Global Macular Degeneration Treatment Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032

The global macular degeneration treatment market size was estimated to be US$ 9.1 Billion in 2022 and is expected to reach US$ 21 Billion by 2032 at a CAGR of 8.7%. 

Macular degeneration is otherwise called age-related macular degeneration (AMD) and is a neurodegenerative visual issue that obliterate the piece of the eye called the macula which gives sharp, focal vision required for seeing items, evidently. Ordinarily, after the age of sixty, there is an onset of an eye illness that can slowly annihilate the macula, the centerpiece of the retina, further impeding the focal vision of the eye. Age-related macular degeneration (AMD) causes uncommon visual deficiency as it influences the focal point of the eye.

Only a couple of authorized medications are accessible for the treatment of the issue in the market. Presently, anti-VEGF therapy is the most common and expected treatment for wet AMD, which is the intermittent eye (intravitreal) injection of a compound alluded to as anti-VEGF. As articulated by, The International Agency for the Prevention of Blindness (IAPB), AMD is the third most common reason for visual impairment across the globe. It is the significant reason for visual impairment in higher-pay nations with geriatric populations. AMD represents almost 5% of visual impairment across the globe. The significant danger factors that lead to the rising occurrences of AMD incorporate hereditary factors, age, and tobacco smoking.

Developing markets with neglected clinical necessities and expanding geriatric population are relied upon to bring new development roads for significant market players working in the worldwide macular degeneration treatment market. North America ruled the worldwide macular degeneration treatment market in 2020. Latin America is projected to observe moderate development over the estimate time frame. Progression in treatment, for example, cell therapy can improve the vision is likewise going to be major factors that drive the market during forecasted period.

global macular degeneration treatment market Value Share Analysis, by Geography (2021)

The report titled “global macular degeneration treatment market  - Global Market Share, Trends, Analysis and Forecasts, 2022-2032”  wherein 2020 is historic period, 2021 is the base year, and 2022 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global macular degeneration treatment market. Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market.

The global macular degeneration treatment market is segmented based on the type, route of administration, and distribution channel. Based on type, the market is classified into dry AMD and wet AMD. Based on the route of administration, the market is classified into intra vitreal and intravenous. Based on the distribution channel, the market is classified into retail pharmacies, hospital pharmacies, and online pharmacies. Based on geography, the global macular degeneration treatment market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America. North America is sub-segmented into the United States, Canada, and Rest of North America. Europe is sub-segmented into Germany, United Kingdom, Italy, France, Spain, and Rest of Europe. Asia Pacific is sub-segmented into China, Japan, India, Australia, and Rest of Asia Pacific. Middle East & Africa is sub-segmented into Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa. South America is sub-segmented into Brazil and Rest of South America.

The research provides in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment and would identify the segment of the company focusing on global macular degeneration treatment market. Further, market share of prominent companies in the global macular degeneration treatment market would also be estimated.

The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, swot analysis, and research and development focus of all the Macular Degeneration Treatment companies. The global macular degeneration treatment market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution. Product portfolio would focus on all the products under the Macular Degeneration Treatment business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the global macular degeneration treatment market.

The key players of the global macular degeneration treatment market are Hoffman L-Roche AG, Novartis International AG, Regeneron Pharmaceuticals, Inc., Pfizer Inc., and Bausch Health Companies Inc.

Global macular degeneration treatment market Key segments:

Based on Type

• Wet AMD
• Dry AMD

Based on Route of administration

• Intravenous
• Intravitreal

Based on Distribution Channel

• Pharmacies and Drug Stores
• Hypermarket/Supermarket
• Online Stores
• Specialty Store
• Others

By Region

• North America
• U.S.
• Canada
• Rest of North America
• Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• Japan
• China
• India
• Australia
• Rest of APAC
• Middle East & Africa
• UAE
• South Africa
• Saudi Arabia
• Rest of MEA
• South America
• Brazil
• Rest of South America